ASH 2022 | Phase Ib/II trial of siremadlin alone or in combination with DLI in high-risk AML post-alloSCT
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, comments on the Phase Ib/II trial (NCT05447663) exploring whether siremadlin monotherapy or in combination with donor lymphocyte infusion (DLI) can reduce the risk of relapse from allogeneic stem cell transplant (alloSCT) in patients with high-risk acute myeloid leukemia (AML). Siremadlin has shown the ability to augment the graft-versus-leukemia (GvL) effect in murine models and the prospective single-arm study aims to establish its tolerability and efficacy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy; Abbvie: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; JAZZ: Consultancy, Research Funding; Daiichi-Sankyo: Consultancy.
